Primary tumor size as a prognostic factor in duodenal neuroendocrine neoplasms ≤20 mm: a population-based SEER analysis [0.03%]
基于SEER的数据库分析原发肿瘤大小对≤20毫米十二指肠神经内分泌肿瘤预后的影响
Giuseppe Lamberti,Francesco Panzuto,Maria Rinzivillo et al.
Giuseppe Lamberti et al.
Objective: The prognostic value of primary tumor size in duodenal neuroendocrine neoplasms (dNENs) ≤20 mm remains uncertain. Although size is used to guide management, its independent effect on survival is unclear. ...
Einas Mohamed,Rosalind Eeles,Terri McVeigh et al.
Einas Mohamed et al.
Summary: Pathogenic germline variants in the genes encoding the various subunits of the succinate dehydrogenase (SDH) enzyme complex are strongly associated with hereditary phaeochromocytomas and paragangliomas (PPGLs). G...
Patient-reported symptom and urgent healthcare use in neuroendocrine tumors [0.03%]
神经内分泌肿瘤患者的症状和紧急医疗使用状况
Julie Hallet,Christopher Noel,Rinku Sutradhar et al.
Julie Hallet et al.
Background: Patients with neuroendocrine tumors (NETs) have a high burden of symptoms persisting over years after diagnosis. Patient-reported outcome measures are routinely screened for in oncology practice but seldom use...
Cabergoline monotherapy in GH- and PRL-cosecreting pituitary adenomas [0.03%]
单用卡麦角林治疗生长激素与催乳素联合分泌的垂体腺瘤
James M McNeil,Nicholas C Candy,Alistair K Jukes et al.
James M McNeil et al.
Functional pituitary tumours, also called pituitary neuroendocrine tumours (PitNETs), typically produce a single hormone, based on the cell lineage from which they arise in the anterior pituitary. Pituitary adenoma dual hypersecretion is le...
Mitotane dosage, plasma levels, and anthropometric measurements in pediatric adrenocortical carcinoma [0.03%]
米托坦剂量、血药浓度及儿科肾上腺皮质癌患者的体格测量数据
Maria Riedmeier,Heidi Frey,Sonir R Antonini et al.
Maria Riedmeier et al.
Objective: Mitotane is an effective treatment for advanced adrenocortical carcinoma (ACC). Given the limited pediatric data available, this study aims to evaluate the associations between mitotane dosage, plasma drug leve...
Distinguishing neuroendocrine tumor grade 3 from neuroendocrine carcinoma in gastroenteropancreatic high-grade neoplasms [0.03%]
胃肠胰高级别神经内分泌肿瘤的分级：神经内分泌肿瘤分级3级与神经内分泌癌的区别
Zandra Ankers,L Samuel Hellgren,Adam Stenman et al.
Zandra Ankers et al.
Objective: High-grade neuroendocrine neoplasms (NENs) with a Ki-67 index >20% are currently classified as either grade 3 neuroendocrine tumors (NET G3) or neuroendocrine carcinomas (NEC). This study evaluates whether this...
Maribel Del Olmo-García,Grace Kong,HuiLi Wong et al.
Maribel Del Olmo-García et al.
Objective: To assess the prevalence, pre-procedure biomarkers, and management of carcinoid crisis (CC) in a cancer-specific hospital. Design: ...
Real-world outcomes of lower lenvatinib doses in advanced neuroendocrine tumors: a multinational retrospective study [0.03%]
低剂量仑伐替尼治疗晚期神经内分泌肿瘤的现实世界结果：一项跨国回顾性研究
G R Almeida,G K Zanetta,J M O&#x;Connor et al.
G R Almeida et al.
Objective: Neuroendocrine tumors (NET) are heterogeneous neoplasms with increasing incidence and limited treatment options for advanced, progressive disease. Lenvatinib, a multitargeted TKI, demonstrated high efficacy but...
Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies [0.03%]
神经内分泌肿瘤中GLP-1受体的表达差异及其对肠降糖素治疗的意义
Po Hien Ear,Sophia A Hueser,Reese E Townsend et al.
Po Hien Ear et al.
Neuroendocrine neoplasms (NENs) are rare cancers originating in various organs and are further classified as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Commonly used drugs su...
HbA1c screening in patients with early breast cancer receiving endocrine therapy [0.03%]
内分泌治疗的早期乳腺癌患者的糖化血红蛋白筛查
Lærke Nissen,Stine Blaabjerg Skovbjerg,Jonas Busk Holm et al.
Lærke Nissen et al.
Objective: Type 2 diabetes increases the risk of developing breast cancer, while endocrine therapy for early breast cancer may elevate the risk of type 2 diabetes. Studies suggest screening patients with early breast canc...